TheraRadar
Data updated: Jun 28, 2026

LEVOCETIRIZINE DIHYDROCHLORIDE · TARO

Respiratory Approved 2007-05-25

Uses temporarily relieves these symptoms due to hay fever or other respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat

Source: FDA Label
22
Indications
--
Phase 3 Trials
19
Years on Market

LEVOCETIRIZINE DIHYDROCHLORIDE Approval History

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
155 FDA actions from 2010 to 2026
May 2026 SUPPL
Label · Labeling
Jan 2026 SUPPL
Label · Labeling
Jul 2025 SUPPL
Label · Labeling

What LEVOCETIRIZINE DIHYDROCHLORIDE Treats

1 indications

LEVOCETIRIZINE DIHYDROCHLORIDE is approved for 1 conditions since its original approval in 2010. These indications span multiple therapeutic areas including oncology, immunology, and more.

Source: FDA Label

LEVOCETIRIZINE DIHYDROCHLORIDE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to LEVOCETIRIZINE DIHYDROCHLORIDE

3 of 19

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ADVAIR DISKUS 100/50
FLUTICASONE PROPIONATE
1 shared
GSK
Shared indications:
ADVAIR DISKUS 250/50
FLUTICASONE PROPIONATE
1 shared
GSK
Shared indications:
ADVAIR DISKUS 500/50
FLUTICASONE PROPIONATE
1 shared
GSK
Shared indications:
📋

Clinical Trial Registry

4 trials
Trial Sponsor ID Phase Status Title
NCT04699604 HAS3 STUDY00001262 5R01HD100545-05 Ph 3 recruiting A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)
NCT00621959 results posted A00430 Ph 4 completed A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis
NCT01567501 Ipca/ARL/059 Ph 1 completed Bioequivalence Study of Levocetirizine Dihydrochloride Tablets 5 mg Under Fed Condition
NCT00653224 results posted A00431 Ph 4 completed A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

LEVOCETIRIZINE DIHYDROCHLORIDE FDA Label Details

Indications & Usage

Uses temporarily relieves these symptoms due to hay fever or other respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat

Looking for the branded version?

LEVOCETIRIZINE HYDROCHLORIDE

Full clinical data, patents, trials, and competitive landscape for levocetirizine dihydrochloride.

See LEVOCETIRIZINE HYDROCHLORIDE

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.